Evidence map›Paper›PMID 32839836›Full record

ArticleJournal of cancer research and clinical oncology2021

Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy.

M Markus, A Abendroth, R Noureddine, A Paul, S Breitenbuecher, I Virchow, K W Schmid, P Markus, B Schumacher, M Wiesweg and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. P-move: a randomized control trial of exercise in patients with advanced pancreatic or biliary tract cancer (aPBC) receiving beyond first-line chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Biomimetic nanoparticles for tumor immunotherapy.Frontiers in bioengineering and biotechnology · 2022
    Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

M MarkusWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
A AbendrothWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
R NoureddineWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
A PaulWest German Cancer Center, Department of General, Visceral and Transplant Surgery, University Hospital Essen, Essen, Germany.
S BreitenbuecherInstitute for Quality Assurance, University Hospital Essen, Essen, Germany.
I VirchowWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
K W SchmidWest German Cancer Center, Institute of Pathology Essen, University Hospital Essen, Essen, Germany.
P MarkusDepartment of General Surgery and Traumatology, Elisabeth Hospital Essen, Essen, Germany.
B SchumacherDepartment of Gastroenterology, Elisabeth Hospital Essen, Essen, Germany.
M WieswegWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
J WendlingWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
B MendeCentral Pharmacy, University Hospital Essen, Essen, Germany.
J T SivekeGerman Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
M SchulerWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
S KasperWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany. stefan.kasper-virchow@uk-essen.de.ORCID http://orcid.org/0000-0002-5947-8733
Essen University Hospital · DEElisabeth-Krankenhaus Essen · DE

Funding

Bundesministerium für Bildung und Forschung German Cancer ConsortiumDeutsche Krebshilfe 110534
6 · The paper itself

Abstract

purposeThe prognosis of patients with advanced pancreatic ductal adenocarcinoma (PDAC) remains dismal. New cytotoxic agents such as nab-paclitaxel and liposomal irinotecan (nal-Iri) have extended the armamentarium of therapeutic options in the last years. Nowadays, sequential therapeutic strategies with moderately toxic chemotherapeutic protocols can be administered to the patients. However, prognostic and predictive biomarkers are still missing to identify those patients, which profit most from a "continuum of care" concept rather than receiving intensive first-line protocols such as FOLFIRINOX. To this end, we retrospectively evaluated the impact of the systemic inflammation as one essential hallmark of cancer in patients with advanced PDAC treated with sequential systemic.

methodsA cohort of 193 PDAC patients treated at our center from January 2005 to August 2011 were retrospectively evaluated for the following systemic inflammatory response (SIR) markers: neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR) C-reactive protein (CRP), and the modified Glasgow Prognostic Score (mGPS). SIR markers were correlated with clinico-pathological findings, response to chemotherapy and overall survival (OS) using Kaplan-Meier curves and Cox proportional models.

resultsAll evaluated SIR markers were significantly associated with OS in patients with metastatic disease but not in patients with locally advanced PDAC. Interestingly, all SIR markers were only prognostic in patients not receiving antibiotics as surrogate marker for systemic bacterial infections. Based on the evaluated SIR markers, we propose a new Systemic Inflammation Score (SIS), which significantly correlated with reduced OS (HR: 3.418 (1.802-6.488, p < 0.001)) and the likelihood of receiving further-line systemic therapies (p = 0.028).

conclusionRoutinely assessed SIR biomarkers have potential to support therapeutic decision making in patients with metastatic PDAC.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Pancreatic DuctalC-Reactive ProteinFemaleHumansInflammationLymphocytesMaleMiddle AgedNeutrophilsPalliative CarePancreatic NeoplasmsPrognosisRetrospective StudiesC-Reactive ProteinInflammationPancreatic cancerPrognosis

Identifiers

PMID32839836
PMCPMC7817578
OpenAlexW3081378287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.